Bone disease in myeloma

Area of Science:

• Oncology
• Pharmacology
• Bone Metabolism

Background:

• Multiple myeloma frequently causes osteolytic bone destruction.
• Pamidronate is the only FDA-approved drug for treating bone complications in multiple myeloma.
• Current standard treatment involves monthly 90 mg intravenous pamidronate infusions over 4 hours.

Purpose of the Study:

• To review the efficacy and safety of pamidronate for managing bone complications in multiple myeloma.
• To provide recommendations on the optimal duration, dosage, and administration of pamidronate.
• To discuss the potential benefits of pamidronate in earlier stages of multiple myeloma and its antimyeloma effects.

Main Methods:

• Review of recent studies and randomized trials comparing pamidronate to placebo.
• Analysis of safety data regarding infusion rates, dosage adjustments, and renal function.
• Evaluation of clinical trial results for oral bisphosphonates and other emerging agents.

Main Results:

• Pamidronate demonstrated sustained benefits in preventing bone loss and complications over a 21-month trial.
• Shorter infusion times (2 hours) were found to be safe.
• Higher doses, more frequent, or rapid infusions were associated with adverse renal effects (albuminuria, azotemia).
• Pamidronate can be safely administered to patients with impaired renal function.
• Oral bisphosphonates showed inconsistent results due to poor absorption and tolerability.
• Zoledronic acid shows promise but requires further evaluation for skeletal complication prevention.

Conclusions:

• Indefinite continuation of monthly intravenous pamidronate is recommended for multiple myeloma patients to prevent skeletal morbidity.
• Pamidronate should be administered at 90 mg monthly, avoiding modifications that increase renal toxicity risk.
• The drug is likely beneficial for all stages of multiple myeloma, including those without overt bone involvement, due to potential antimyeloma effects.